ClinicalTrials.gov record
Completed Phase 2 Interventional

Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin Infections

ClinicalTrials.gov ID: NCT05599295

Public ClinicalTrials.gov record NCT05599295. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 7:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-Label, Evaluator-Blinded, Randomized Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous Oritavancin for the Treatment of Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections

Study identification

NCT ID
NCT05599295
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Melinta Therapeutics, LLC
Industry
Enrollment
118 participants

Conditions and interventions

Interventions

  • Kimyrsa Drug
  • Orbactiv Drug

Drug

Eligibility (public fields only)

Age range
3 Months to 11 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 14, 2023
Primary completion
Nov 19, 2025
Completion
Nov 19, 2025
Last update posted
Nov 24, 2025

2023 – 2025

United States locations

U.S. sites
2
U.S. states
2
U.S. cities
2
Facility City State ZIP Site status
Tampa General Hospital Tampa Florida 33606
Nationwide Children's Hospital Columbus Ohio 43205-2664

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05599295, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 24, 2025 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05599295 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →